Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15351 - 15375 of 15410 in total
Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Experimental
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
UK-500,001 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
Sarconeos is an activator of the MAS receptor.
Investigational
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Investigational
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).
Investigational
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Displaying drugs 15351 - 15375 of 15410 in total